🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

From preclinical efficacy to 2022 updated CROWN trial, lorlatinib is t... sciencedirect.com/science/articl… Finally after 6 months now the slides I used can be shared. Galley proof final version should be available soon. Misako Nagasaka ALK+ International ALK Positive LCAM Coalition Targeted Oncology

Critical Review in Oncology Hematology. Figures to argue for using Lorlatinib as 1L treatment of advanced ALK+NSCLC. Open access. ALK+ International ALK Positive PMID:37187318.

Additional exclusions of ROS1 fusions | LCTT Dove Medical Press dovepress.com/the-additional…. A food for thought editorial on harmonizing ICIs ceoteria for use in EGFR/ALK/ROS1/TET+ NSCLC.

From ASCEND-5 to ALUR to ALTA-3 | LCTT Dove Medical Press dovepress.com/from-ascend-5-… ALK+ International ALK Positive

The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FD… pubmed.ncbi.nlm.nih.gov/37383584/

From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation A… pubmed.ncbi.nlm.nih.gov/37377783/ ALK Positive ALK+ International

Quick editorial. Anticiapte Lorlatinib will have a long median PFS among Asians than alectinib despite the excellent PFS achieved by ALESIA. pubmed.ncbi.nlm.nih.gov/37440867/ ALK Positive ALK+ International

Congratulations to Dr. Nagasaka for bring the manuscript to the finish line. Pan-tumor survey of RET fusions as detected by next-generation RNA seq... sciencedirect.com/science/articl… Misako Nagasaka @DrSteveMartin Chul Kim Mark Socinski

Letter to Editor. Re “de Leeuw SP, et al. Analysis of Serious Weight G... sciencedirect.com/science/articl…. A clinical situation that is worth studying. Incretins for ALK TKI induced excessive weight gain? ALK Positive ALK+ International

MARIPOSA performed better among Asians. LA arm got to 27.5 months and a HR close to FLAURA-2. Also Osi performed as well as Laz. 18.2 m vs.18.3 m. #esmo2023asia

EXCLAIM-2 presidential symposium. Chemotherapy over performed, PFS 9.6 months. HR=1.04. Still searching for EGFR TKI monotherapy in EGFRex20ins.#esmoasia2023

20 papers/20 years/20th anniversary of EGFR mutations discovery. 21 panel members, 87 candidate papers, 59 ranked, top 30 annotated. Goal is to serve as a "syllabus" for training of future thoracic oncologists Dove Medical Press dovepress.com/article_metric… EGFRm NSCLC Dr. Antonio Calles 🫁🚭

The 20 papers that shaped the advancement of EGFR+ NSCLC treatment since the discovery of EGFR mutations. Commemoration of 20th anniversary of EGFR mutations discovery | LCTT Dove Medical Press dovepress.com/top-20-egfr-ns… Dove Medical Press Xiuning Le MD PhD Elaine Shum Misako Nagasaka

Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activa… pubmed.ncbi.nlm.nih.gov/38938224/ Now indexed in pubmed. LCAM Coalition LungCancerFoundation EGFRm NSCLC EGFR Resisters EGFR Resisters Research Summit

Systematic review & network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as 1L treatment for advanced ALK-NSCLC. lungcancerjournal.info/article/S0169-… ALK+ International ALK Positive LCAM Coalition

Glad to be part of the team with my colleague Dr. Misako Nagasaka Misako Nagasaka that got the another oncology drug approved. Agree with Dr. Stephen Liu Stephen V Liu, MD need RNA NGS to find a needle in the haystack.

TROPION Lung 01 and 05 pooled analysis of EGFR+ NSCLC post EGFR TKI. mPFS 5.8 months.

PACIFIC-5. PFS benefit but no OS benefit. #ESMOASIA2024

Asians in Asia had longer PFS but shorter OS in FLAURA-2 when compared to global population. #ESMOASIA2024

Zongertinib #esmoasia2024 update. Potentially the first HER2TKI approved for HER2 exon 20 insertions in NSCLC.